Quantification of Amlexanox in Beagle Dog Plasma by LC-MS/MS and Its Application in a Comparative Pharmacokinetic Study of Conventional and Sustained-Release Tablets.
The clinical development of a sustained-release amlexanox formulation with reduced dosing frequency and improved patient compliance is supported and support the clinical development of a sustained-release amlexanox formulation with reduced dosing frequency and improved patient compliance.
Abstract
Amlexanox, a 5H-benzopyranopyridine derivative with emerging therapeutic potential in metabolic and inflammatory diseases, lacks a validated analytical method for pharmacokinetic studies in beagle dogs. A sensitive LC-MS/MS method was developed and validated for amlexanox in beagle dog plasma according to ICH M10 guidelines. Propranolol served as internal standard. Samples were processed by protein precipitation, and separation was achieved on a CAPCELL PAK C18 column using gradient elution with water and acetonitrile (both containing 0.2% formic acid) at 400 μL/min. Detection used positive electrospray ionization with MRM of m/z 299.0 → 281.0 for amlexanox and m/z 260.0 → 116.1 for IS. The method showed good linearity over 40-2000 ng/mL (R2 > 0.99). All validation parameters met acceptance criteria. The method was applied to a three-period fixed-sequence study in beagle dogs (n = 3, male) comparing intravenous injection (1 mg/kg), conventional tablets (75 mg), and sustained-release tablets (150 mg). The sustained-release formulation prolonged Tmax (3.67 vs. 1.00 h) and residence time (two-fold increase in t1/2 and MRT), and improved absolute bioavailability from 25.36% to 33.09% (relative bioavailability: 151.30%). These findings support the clinical development of a sustained-release amlexanox formulation with reduced dosing frequency and improved patient compliance.
A sensitive, reliable, and rapid UPLC–MS/MS method was developed and validated for the simultaneous determination of ensartinib and M465 in rat plasma and applied to a rat pharmacokinetic study and provides useful analytical support for further preclinical investigations of ensartinib and its major metabolite.
Shi-Qi Jiang, Yan Chen, Lu Cao et al.· Drug Design, Development and...· 0 citations
A sensitive and reliable ultra-high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of ibuprofen in plasma to investigate the pharmacokinetics of ibuprofen after oral administration of ibuprofen sustained-release capsules.
Mei-Ah Yang, Kui He, Yu-Jie Mo et al.· Acta Chromatographica· 0 citations
A rapid isocratic LC-MS/MS method for quantifying busulfan in human plasma was developed and validated. Plasma samples were processed by protein precipitation with acetonitrile using busulfan-d8 as the internal standard. Separation was performed on a Kinetex C18 column (2.1 × 50 mm, 5 µm; Phenomenex) with isocratic elu...
The method's potential for retrospective urinary screening of Z-drug exposure in forensic and clinical toxicology is supported, and its potential for retrospective urinary screening of Z-drug exposure in forensic and clinical toxicology is supported.
Varsha Chauhan, Manu Sharma, Murtada Taha et al.· Biomedical chromotography· 0 citations
The developed LC-MS/MS method for quantifying repotrectinib in rat plasma exhibited reliability and suitability for pharmacokinetic evaluation, as evidenced by a Cmax of 52.30±0.79 ng/ml at Tmax of 5 h in rats.
Sathish Sabbani, G. Chakravarthi, Narender Malothu· International Journal of App...· 0 citations
The first validated liquid chromatography tandem mass spectrometry (LC-MS/MS) bioanalytical method for the quantification of atirmociclib in mouse plasma is reported, validated in compliance with international council for harmonisation-M10 (ICH-M10) guidelines.
Ashwani Gaur, U. Patel, Ashutosh Gavali et al.· Journal of chromatography. B...· 0 citations
Related blog posts
MIT News · Artificial Intelligence· news.mit.eduNov 9, 2026
A new machine-learning framework aims to improve the success rate of computational protein design while moving away from results that reproduce sequences found in nature.